Physician profile

Edwin Heidelberger

Internal Medicine · Springville, NY

NPI 1821070970

$2,991.88

in general payments reported to CMS, 2019-2025

36 companies · $735 in 2025

The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,008.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $415.52 2019-2025 Shingrix, Trelegy Ellipta
Novo Nordisk INC $369.19 2019-2025 Ozempic, Rybelsus, Wegovy
Amgen INC. $213.21 2022-2025 Otezla, Repatha, Otezla
Abbvie INC. $205.55 2022-2025
Pfizer INC. $191.43 2019-2025
Exact Sciences Corporation $171.57 2023-2025 Cologuard Collection Kit
Lilly USA, LLC $162.68 2019-2025 Jardiance, Mounjaro
Gilead Sciences, INC. $129.43 2022-2023
Phathom Pharmaceuticals, INC. $114.71 2024-2025 Voquezna
Boehringer Ingelheim Pharmaceuticals, INC. $110.32 2019-2024 Ofev
Merck Sharp & Dohme LLC $96.26 2019-2025 Gardasil 9, Vaxneuvance, Capvaxive
Edwards Lifesciences Corporation $77.82 2022-2025 Sapien 3 Ultra Resilia
Abbott Laboratories $76.62 2021-2025 Freestyle Libre 3
Novartis Pharmaceuticals Corporation $59.08 2019-2022
Astellas Pharma US INC $55.30 2023-2025 Veozah
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $55.05 2022-2023
Dexcom, INC. $48.32 2022-2024 Dexcom G6 Transmitter
Shield Therapeutics INC $38.74 2023-2024 Accrufer
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $34.43 2023 Xifaxan
Grifols USA, LLC $32.90 2019-2020
Biohaven Pharmaceutical Holding Company LTD. $31.32 2022
Sanofi-Aventis U.S. LLC $28.89 2022
E.R. Squibb & Sons, L.L.C. $26.53 2019-2023 Eliquis
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $25.98 2025 Caplyta
Alnylam Pharmaceuticals INC. $24.40 2023 Onpattro
Astrazeneca Pharmaceuticals LP $24.12 2019
Cipher Pharmaceuticals US LLC $19.52 2025 Natroba, Spinosad
Janssen Pharmaceuticals, INC $19.50 2019
Insulet Corporation $18.66 2024 Omnipod
Aimmune Therapeutics, INC. $17.86 2024
Alkermes, INC. $17.61 2023 Vivitrol
Alk-Abello, INC $17.36 2023 Grastek, Odactra, Ragwitek
Teva Pharmaceuticals USA, INC. $16.96 2019
Sumitomo Pharma America, INC. $16.72 2025 Gemtesa
Sunovion Pharmaceuticals INC. $14.28 2019
Lundbeck LLC $14.04 2024 Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Edwin Heidelberger

$2,991.88

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/354679/edwin-heidelberger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.